Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas
RODRIGUEZ, Jose, MUNSELL, Mark, ROMAGUERA, Jorge, CABANILLAS, Fernando F, CHAMPLIN, Richard E, KHOURI, Issa F, YAZJI, Salim, HAGEMEISTER, Fredrick B, YOUNES, Anas, ANDERSSON, Borje, GIRALT, Sergio, GAJEWSKI, James, DE LIMA, Marcos, COURIEL, Daniel
Published in Journal of clinical oncology (01.09.2001)
Published in Journal of clinical oncology (01.09.2001)
Get full text
Journal Article
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
RICART, Alejandro D, TOLCHER, Anthony W, LIU, Glenn, HOLEN, Kyle, SCHWARTZ, Garry, ALBERTINI, Mark, WEISS, Geoffrey, YAZJI, Salim, NG, Chee, WILDING, George
Published in Clinical cancer research (01.12.2008)
Published in Clinical cancer research (01.12.2008)
Get full text
Journal Article
Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma
Wang, Michael L., Frigault, Matthew J., Yazji, Salim, Katz, Yisrael, Robinson, James, Breitmeyer, James B., Mei, Matthew G., Jacobson, Caron A
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer
Yu, Evan Y., Nordquist, Luke, Yazji, Salim, Katz, Yisrael, Coates, Elisabeth, Vandross, Andrae Lavon, Salkeni, Mohamad Adham, Emamekhoo, Hamid, Heath, Elisabeth I., de Kouchkovsky, Ivan, Lang, Joshua Michael, Nelson, Peter, Breitmeyer, James Bradley, Fong, Lawrence, De Bono, Johann S.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer
Yu, Evan Y., Yazji, Salim, Katz, Yisrael, Coates, Elisabeth, Nordquist, Luke T., Vandross, Andrae Lavon, Salkeni, Mohamad Adham, Lang, Joshua Michael, Nelson, Peter, Breitmeyer, James Bradley, Fong, Lawrence, De Bono, Johann S.
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
Lee, Hun Ju, Choi, Michael Y., Siddiqi, Tanya, Rhodes, Joanna M., Wierda, William G., Isufi, Iris, Tuscano, Joseph M, Lamanna, Nicole, Subbiah, Suki, Koff, Jean L., Leslie, Lori, Goldenberg, Alec, Chung, Gina G, Breitmeyer, James B., Yazji, Salim, Wang, Michael, Jamieson, Catriona, Kipps, Thomas J.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
Rosen, Lee S., LoRusso, Patricia, Ma, Wen Wee, Goldman, Jonathan W., Weise, Amy, Colevas, A. Dimitrios, Adjei, Alex, Yazji, Salim, Shen, Angela, Johnston, Stuart, Hsieh, Hsin-Ju, Chan, Iris T., Sikic, Branimir I.
Published in Investigational new drugs (01.10.2016)
Published in Investigational new drugs (01.10.2016)
Get full text
Journal Article
Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Lee, Hun Ju, Choi, Michael Y., Siddiqi, Tanya, Rhodes, Joanna Meehan, Wierda, William G., Isufi, Iris, Tuscano, Joseph M., Lamanna, Nicole, Subbiah, Suki, Koff, Jean Louise, Leslie, Lori Ann, Goldenberg, Alec, Chung, Gina G., Yazji, Salim, Wang, Yao, Breitmeyer, James Bradley, Wang, Michael, Jamieson, Catriona, Kipps, Thomas J.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
Lee, Hun Ju, Choi, Michael, Siddiqi, Tanya, Barrientos, Jacqueline, Wierda, William G., Isufi, Iris, Tuscano, Joseph, Lamanna, Nicole, Subbiah, Suki, Koff, Jean L., Leslie, Lori A., Goldenberg, Alec, Chung, Gina G, Breitmeyer, James B., Yazji, Salim, Wang, Yao, Wang, Michael, Jamieson, Catriona, Kipps, Thomas J.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Abstract 2475: A novel class of fully human monoclonal anti-oxMIF antibodies penetrates metastases and accumulates in tumor tissue
Schinagl, Alexander, Thiele, Michael, Douillard, Patrice, Adib, Deyaa, Liu, Xiaochun, Yazji, Salim, Scheiflinger, Friedrich, Kerschbaumer, Randolf
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients
Douillard, Patrice, Thiele, Michael, Schinagl, Alexander, Halama, Niels, Jaeger, Dirk, Yazji, Salim, Scheiflinger, Friedrich, Kerschbaumer, Randolf
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3 rd or 4 th line treatment in metastatic colorectal cancer (mCRC)
Liu, Xiaochun, Adib, Deyaa Rafaat, Barak, Hila, Goldberg, Richard M., Yazji, Salim
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors
Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Liu, Xiaochun, Yazji, Salim, Jaeger, Dirk, Adib, Deyaa, Kerschbaumer, Randolf, Tsimberidou, Apostolia Maria
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors
Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Neils, Ramanathan, Ramesh K., Sarantopoulos, John, Liu, Xiaochun, Yazji, Salim, Jaeger, Dirk, Adib, Deyaa Rafaat, Kerschbaumer, Randolf, Tsimberidou, Apostolia Maria
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
Rosen, Lee, LoRusso, Patricia, Ma, Wen Wee, Goldman, Johathan, Weise, Amy, Colevas, A. Dimitrios, Adjei, Alex, Yazji, Salim, Shen, Angela, Johnston, Stuart, Gates, Mary R., Jones, Cheryl, Musib, Luna, De Crespigny, Alex, Chan, Iris, Sikic, Branimir
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Get full text
Journal Article
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study
Ricart, Alejandro D, Tolcher, Anthony W, Liu, Glenn, Holen, Kyle, Schwartz, Garry, Albertini, Mark, Weiss, Geoffrey, Yazji, Salim, Ng, Chee, Wilding, George
Published in Clinical cancer research (01.12.2008)
Published in Clinical cancer research (01.12.2008)
Get full text
Journal Article
Iseganan HCl: a novel antimicrobial agent
Giles, Francis J, Redman, Rebecca, Yazji, Salim, Bellm, Lisa
Published in Expert opinion on investigational drugs (01.08.2002)
Published in Expert opinion on investigational drugs (01.08.2002)
Get more information
Journal Article
ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS
Douillard, Patrice, Kerschbaumer, Randolf, Thiele, Michael, Yazji, Salim
Year of Publication 07.06.2018
Get full text
Year of Publication 07.06.2018
Patent
ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS
YAZJI, Salim, KERSCHBAUMER, Randolf, DOUILLARD, Patrice, THIELE, Michael
Year of Publication 28.03.2018
Get full text
Year of Publication 28.03.2018
Patent